Utility of the 3-tier grouping system for survival discriminatory ability in stage IIA cervical cancer.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
02 2021
Historique:
received: 12 05 2020
revised: 02 06 2020
accepted: 10 06 2020
pubmed: 2 9 2020
medline: 21 4 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

Given the improved survival prediction of a tumor size-based 3-tier grouping system for stage IB cervical cancer under the new staging guidelines, this study examined the survival utility of a tumor size-based 3-tier system for stage T2a cervical cancer. This is a population-based retrospective observational study utilizing the Surveillance, Epidemiology, and End Result Program from 1988 to 2016. Women with stage T2a/N0-1-x/M0-x cervical cancer were grouped by tumor size in a 3-tier system: stage T2a (≤2 cm), T2a (2.1-4.0 cm), and T2a (>4 cm). Survival outcome was examined by non-proportional hazard analysis with restricted mean survival time (RMST) at 5 years. Among 2449 cases, the most common group was T2a (>4 cm) (n = 1,392, 56.8%), followed by T2a (2.1-4 cm) (n = 783, 32.0%) and T2a (≤2 cm) (n = 274, 11.2%). The median follow-up was 5.2 years. The proposed 3-tier system clearly discriminated survival outcome between the groups: average overall survival time during 5 years of follow-up, 51.0, 47.2, and 43.8 months for T2a (≤2 cm), T2a (2.1-4 cm), and T2a (>4 cm) group, respectively (P < 0.001). Adjusted between-group difference of average overall survival time in the 3-tier system (8.8 months, 95% confidence interval [CI] 6.2-11.3, P < 0.001) was larger compared to the between-group difference in the historical 2-tier system (5.9 months, 95%CI 4.2-7.6, P < 0.001). Women in the T2a (≤2 cm) group were more likely to have longer average overall survival time during 5 years of follow-up compared to those in the T2a (2.1-4 cm) group (3.6 months, 95%CI 1.1-6.1, P = 0.004). Our study suggests that a tumor size-based 3-tier grouping system may be useful for improved prediction of survival in stage IIA cervical cancer.

Identifiants

pubmed: 32868150
pii: S0748-7983(20)30538-2
doi: 10.1016/j.ejso.2020.06.014
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-337

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Research funding, MSD (S.M.); advisory board, Tesaro, GSK (M.K.); honorarium, Chugai, textbook editorial expense, Springer, and investigator meeting attendance expense, VBL therapeutics (K.M.); consultant, Quantgene (L.D.R.); none for others.

Auteurs

Koji Matsuo (K)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu.

David J Nusbaum (DJ)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Maximilian Klar (M)

Department of Obstetrics and Gynecology, University of Freiburg, Freiburg, Germany.

Shinya Matsuzaki (S)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Brendan H Grubbs (BH)

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Hiroko Machida (H)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.

Ikuo Konishi (I)

Department Obstetrics and Gynecology, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.

Mikio Mikami (M)

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.

Lynda D Roman (LD)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH